Novo Nordisk A/S CagriSema 1.0 mg/1.0 mg achieved superior weight loss of 12.4%* versus tirzepatide 5 mg of 9.1%* and non-inferior HbA1c reduction at week 60 in adults with type 2 diabetes in REIMAGINE 5. CagriSema 1.0 mg/1.0 mg delivered significant and clinically meaningful weight loss of 21%* versus placebo at week 68 in adults living with overweight or obesity in REDEFINE 9. In both trials, CagriSema was well tolerated overall, with a safety profile consistent with previous studies.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.